Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Protalix BioTherapeutics (PLX) Cash from Investing Activities (2016 - 2025)

Historic Cash from Investing Activities for Protalix BioTherapeutics (PLX) over the last 17 years, with Q3 2025 value amounting to -$504000.0.

  • Protalix BioTherapeutics' Cash from Investing Activities fell 10247.95% to -$504000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$16.6 million, marking a year-over-year decrease of 18632.74%. This contributed to the annual value of $4.2 million for FY2024, which is 12525.88% up from last year.
  • As of Q3 2025, Protalix BioTherapeutics' Cash from Investing Activities stood at -$504000.0, which was down 10247.95% from -$438000.0 recorded in Q2 2025.
  • Protalix BioTherapeutics' Cash from Investing Activities' 5-year high stood at $37.4 million during Q4 2021, with a 5-year trough of -$30.7 million in Q1 2021.
  • Moreover, its 5-year median value for Cash from Investing Activities was -$222000.0 (2023), whereas its average is $7473.7.
  • As far as peak fluctuations go, Protalix BioTherapeutics' Cash from Investing Activities surged by 291343.28% in 2021, and later plummeted by 437953.22% in 2024.
  • Quarter analysis of 5 years shows Protalix BioTherapeutics' Cash from Investing Activities stood at $37.4 million in 2021, then tumbled by 86.77% to $5.0 million in 2022, then tumbled by 106.9% to -$342000.0 in 2023, then tumbled by 4379.53% to -$15.3 million in 2024, then soared by 96.71% to -$504000.0 in 2025.
  • Its Cash from Investing Activities stands at -$504000.0 for Q3 2025, versus -$438000.0 for Q2 2025 and -$312000.0 for Q1 2025.